Lukas Biomedical (ROCO:6814) EBIT: NT$-80.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
66 GF Score
Price NT$24.70
GF Value NT$21.77
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical EBIT?

Lukas Biomedical ROCO:6814 +4.45% 66 EBIT is NT$-80.6 Mil as of Dec. 2025. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.77 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Lukas Biomedical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$-39.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-80.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lukas Biomedical's annualized ROC % for the quarter that ended in Dec. 2025 was -19.29%. Lukas Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -90.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lukas Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -6.98%.

Lukas Biomedical  (ROCO:6814) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lukas Biomedical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-80.114 * ( 1 - 0% )/( (407.115 + 423.369)/ 2 )
=-80.114/415.242
=-19.29 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=452.483 - 26.772 - ( 40.284 - max(0, 86.899 - 105.495+40.284))
=407.115

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=426.803 - 25.919 - ( 34.747 - max(0, 114.811 - 92.326+34.747))
=423.369

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Lukas Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-78.986/( ( (56.376 + max(37.175, 0)) + (50.492 + max(30.563, 0)) )/ 2 )
=-78.986/( ( 93.551 + 81.055 )/ 2 )
=-78.986/87.303
=-90.47 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.61 + 40.87 + 13.731) - (26.772 + 0 + 1.264)
=37.175

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(11.519 + 35.386 + 10.674) - (25.919 + 0 + 1.097)
=30.563

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lukas Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-80.554/1153.468
=-6.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical EBIT Related Terms

Lukas Biomedical EBIT Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical EBIT Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -43.42 -47.00 -44.20 -91.43 -80.55

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.10 -39.00 -52.44 -41.06 -39.49

ROCO:6814 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Lukas Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lukas Biomedical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's EV-to-EBIT falls into.


ROCO:6814
66GF Score
Lukas Biomedical Inc ROCO:6814
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-80.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-80.6 Mil mean?
Lukas Biomedical (ROCO:6814) has a EBIT of NT$-80.6 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lukas Biomedical.
Is Lukas Biomedical's EBIT too high?
Lukas Biomedical's current EBIT is NT$-80.6 Mil. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's EBIT compare to VRTX and REGN?
Lukas Biomedical's EBIT of NT$-80.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lukas Biomedical. Lukas Biomedical's current EBIT is NT$-80.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.70 — trading 13.5% above its estimated fair value. The current EBIT is NT$-80.6 Mil. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current EBIT is NT$-80.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$24.70 is trading 13.5% above its estimated GF Value™ of NT$21.77. GuruFocus considers Lukas Biomedical to be Modestly Overvalued.

Key valuation signals for ROCO:6814:

  • EBIT: NT$-80.6 Mil
  • GF Value™: NT$21.77 vs. price of NT$24.70 (13.5% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score

Get the complete analysis for ROCO:6814

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.70
Price
NT$21.77
GF Value